Takeda Pharmaceutical has agreed to divest four type 2 diabetes treatmentsin Japan to Teijin Pharma in exchange for ¥133 B (US$1.3 B). The products include Nesina® (alogliptin), Liovel® (alogliptin/pioglitazone), Inisync® (alogliptin/metformin) and Zafatek® (trelagliptin). The deal marks yet another decision by Takeda to off-load its non-core assets to reduce its debt from its acquisition of Shire, which was completed in January 2019. Since then, Takeda has exceeded its US$10 billion non-core asset divestiture target, announcing 12 deals for a total aggregate value of up to US$12.9 B.